Acute Coronary Syndromes

In patients with a previous history of stroke or heart attack, discontinuation was associated with a 46 percent increased risk—translating to one additional cardiovascular event per year per 36 patients who stopped taking aspirin.

Nicotine in electronic cigarettes boosts the cardiac adrenaline levels of users, which could put them at increased risk for heart disease, according to a new study in the Journal of the American Heart Association.

Based on clinical guidelines, three therapies are often prescribed together following acute MI: angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), beta-blockers and statins. But are they equally important?

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase of 21 percent for suffering a heart attack.

Patients who have suffered a previous heart attack remain at increased risk for another myocardial infarction (MI), cardiovascular death or stroke, with no indication of the risk level waning over time. According to new research, the optimal dose of ticagrelor shows consistent benefits in reducing ischemic risk over five-plus years in heart attack patients, while its added risk for major bleeding events abates over time.

Despite proven survival benefits, roughly two-thirds of heart attack patients forego cardiac rehabilitation, according to a report from the Centers for Disease Control and Prevention (CDC).

National organizations, state governments and local communities have attempted to battle out-of-hospital cardiac arrest (OHCA) by supporting public awareness and improving preparedness, most notably through CPR training and use of automated external defibrillators (AEDs). A recent study—published online July 31 in Resuscitation, the journal of the European Resuscitation Council—examined the effectiveness of the Minnesota Heart Safe Communities program.

New-generation drug-eluting stents (DES) demonstrate long-term safety in women with acute myocardial ischemia (MI), with increased benefits for more severe cases of acute coronary syndrome (ACS), according to a new study.

A registry analysis found that approximately one-third of patients who currently have acute coronary syndrome would have qualified for the IMPROVE-IT trial, which enrolled patients between 2005 and 2010.